Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comparative, Single-Blind, Randomized Study on Quetiapine and Aripiperazole Augmentation in Treatment of Selective Serotonin Reuptake Inhibitor Refractory Obsessive-Compulsive Disorder Publisher Pubmed



Talaei A1 ; Hosseini FF1 ; Aghili Z2 ; Akhondzadeh S3 ; Asadpour E4 ; Mehramiz NJ5 ; Forouzanfar F6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychiatry and Behavioral Sciences Research Center and Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Psychiatric Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. The University of Arizona, College of Medicine, Tucson, 85724, AZ, United States
  6. 6. Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Neuroscience, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Canadian Journal of Physiology and Pharmacology Published:2020


Abstract

Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder, of unknown etiology, that affects 2.5% of the population. An appropriate therapeutic response to conventional treatment is seen. Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therapeutic response. In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments in patients with selective serotonin reuptake inhibitor (SSRI) refractory OCD. The OCD patients were initially treated for 12 weeks with a SSRI. If after 12 weeks their Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) score was more than 16, they were randomly assigned to either the aripiprazole or the quetiapine augmentation group for an additional 12 weeks. There were no significant differences in age, sex, education, marital status, or score of Y-BOCS and Clinical Global Impression-Severity Scale (CGI-S) between groups (p > 0.05) at the outset of the study. Significant differences were noted after 1 month when compared with results at 2, 3, and 4 months in both groups (p < 0.001). Both quetiapine and aripiprazole may be effective and well-tolerated augmentative agents in the treatment of SSRI-refractory OCD. Because of positive results, aripiprazole may be considered more effective and may have a more rapid onset in terms of therapeutic response. © 2020, Canadian Science Publishing. All rights reserved.
Related Docs
1. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)
2. A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder, Psychiatry Research (2019)
3. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
4. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
Experts (# of related papers)
Shahin Akhondzadeh Basti (2)
Mohammadreza Razzaghof (1)